Akero Therapeutics
Compare Akero Therapeutics…Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Akero TherapeuticsEfruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.
Company-specific KPIs and metrics
KPI breakdown data is not available for this company.